---
title: "GALT.US (GALT.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/GALT.US/news.md"
symbol: "GALT.US"
name: "GALT.US"
parent: "https://longbridge.com/zh-HK/quote/GALT.US.md"
datetime: "2026-03-16T05:20:07.029Z"
locales:
  - [en](https://longbridge.com/en/quote/GALT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GALT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GALT.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/GALT.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/GALT.US/news.md)


# GALT.US (GALT.US) — 相關新聞

### [Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT](https://longbridge.com/zh-HK/news/276533210.md)
*2026-02-22T10:42:47.000Z*
> Galectin Therapeutics (GALT) has announced the termination of its seamless Phase 2b/3 study of belapectin for NASH cirrh

### [Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc](https://longbridge.com/zh-HK/news/275364086.md)
*2026-02-09T21:25:59.000Z*
### [Magnera Reports First Quarter Results | MAGN Stock News](https://longbridge.com/zh-HK/news/274873026.md)
*2026-02-04T13:36:00.000Z*
> Magnera Corporation reported its first quarter results, achieving net sales of $792 million and operating income of $14 

### [Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers](https://longbridge.com/zh-HK/news/273285494.md)
*2026-01-21T22:01:52.000Z*
### [Top Galectin Therapeutics Insider Makes Notable Move With Company Stock](https://longbridge.com/zh-HK/news/272485082.md)
*2026-01-14T02:02:11.000Z*
> On January 13, 2026, Galectin Therapeutics' CEO Joel Lewis sold 56,332 shares for $218,568, raising investor interest re

### [Marc Rubin Resigns from Galectin Therapeutics Board](https://longbridge.com/zh-HK/news/272323760.md)
*2026-01-12T22:01:20.000Z*
### [Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock](https://longbridge.com/zh-HK/news/271707319.md)
*2026-01-06T22:41:43.000Z*
> Galectin Therapeutics CEO Joel Lewis sold 27,731 shares of the company's stock at an average price of $3.91, totaling $1